Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platelet function in ACS: P2Y12 monotherapy vs DAPT (Neomindset sub-study)
NCT05767723Phase 4Active, not recruiting
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor and prasugrel in acute coronary syndrome (ACS) (2 arms), sponsored by Hospital Israelita Albert Einstein. Primary endpoint: Platelet function using PFA-100 at 30 days. Started Feb 2023; status: active, not recruiting.
02
Drugs
ticagrelorprasugrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05767723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767723.